FDA pushes back Ascendis' PDUFA for long-acting hormone therapy

Danish biotech Ascendis Biopharma has been working on a treatment for pediatric growth hormone deficiency, but the FDA says they’re going to have to wait a little bit longer before they can make their approval decision.